<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378768</url>
  </required_header>
  <id_info>
    <org_study_id>2029.00</org_study_id>
    <secondary_id>FHCRC-2029.00</secondary_id>
    <secondary_id>GENZ-FHCRC-2029.00</secondary_id>
    <secondary_id>CDR0000500474</secondary_id>
    <nct_id>NCT00378768</nct_id>
  </id_info>
  <brief_title>Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of Thymoglobulin in Patients With Multiple Myeloma Who Are Candidates for Allogeneic or Autologous Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune&#xD;
      system in different ways and stop cancer cells from growing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well antithymocyte globulin works in treating&#xD;
      patients undergoing stem cell transplant for multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate at 4 weeks in patients with multiple myeloma treated with&#xD;
           anti-thymocyte globulin at least 4 to 6 weeks prior to undergoing conditioning therapy&#xD;
           for allogeneic or autologous stem cell transplantation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this drug, in terms of formation of antirabbit antibodies, in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive anti-thymocyte globulin IV over 6 hours on day 1 and over 4 hours on days 3&#xD;
      and 5. Treatment begins 4 to 6 weeks prior to undergoing conditioning therapy for autologous&#xD;
      or allogeneic stem cell transplantation.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTC v2.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formation of antirabbit antibodies</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma&#xD;
&#xD;
          -  Candidate for autologous or allogeneic stem cell transplantation within 1 to 3 months&#xD;
             after study treatment&#xD;
&#xD;
          -  Measurable disease, defined as serum monoclonal protein ≥ 1 g/dL OR urinary light&#xD;
             chain excretion = 500 mg/24 hours&#xD;
&#xD;
          -  No malignant CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Hepatic function ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  DLCO ≥ 50%&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No hypersensitivity to rabbit proteins&#xD;
&#xD;
          -  No symptomatic hyperviscosity syndrome&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 28 days since prior chemotherapy, including prednisone (20 mg&#xD;
             equivalent/day)&#xD;
&#xD;
          -  No prior anti-thymocyte globulin&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William I. Bensinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2011</last_update_posted>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

